Genentech is presenting at #ASRS24, showcasing the latest advancements in #ophthalmology research and treatment. Join us in our commitment to advancing science and improving patient outcomes at our latest sessions. https://lnkd.in/emA4Eur
Genentech Medical’s Post
More Relevant Posts
-
Can Understanding HO-1 in BACH1 Knockout Mice Help Treat Sepsis Better? Raghavan Pillai Raju, Medical College of Georgia at Augusta University, USA, will present a short oral contribution during #RedoxMedicine2024 elaborating on this topic. Dr. Raju will discuss the regulation of HO-1 in BACH1 knockout mice following sepsis. He will provide new insights into the regulatory mechanisms of HO-1 in response to sepsis, potentially informing new therapeutic strategies. Join us on June 27-28, 2024 at Fondation Biermans-Lapôtre, Paris, to learn more! 🔗 Selected Short Orals: https://lnkd.in/gypa9uFD. 🌐 More information: https://lnkd.in/dkNzFQZU. #RedoxMedicieSociety #RedoxMedicine2024 #biomarkers #redoxbiology #redox #antioxidants #innovation #oxidativestress #RedoxResearch
To view or add a comment, sign in
-
-
My PhD thesis work focused on studying the impact of bacterial functional amyloids, like CsgA, in Parkinson's disease causation. Extremely delighted to see that novel therapeutics are being developed to target the gut-brain-axis in neurodegenarative diseases. #gutmicrobiome #gutbrainaxis #neurodegeneration #parkinsonsdisease #alzheimersdisease
Axial’s Vice President, Head of Preclinical R&D, Becca Senter is presenting tomorrow at the 2024 AD/PD - Advances in Science & Therapy International Conference on #Alzheimers and #Parkinsons Disease in Lisbon, Portugal. Learn more: https://adpd.kenes.com/ #ADPD2024
To view or add a comment, sign in
-
-
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Bill Morice, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss testing innovations for Alzheimer’s disease and cognitive impairments, and how laboratorians can responsibly help shape the future of healthcare. https://bit.ly/3WeqAck
Alzheimer’s Disease and Testing Innovations: Bill Morice, M.D., Ph.D.
To view or add a comment, sign in
-
👨🔬Meet Dr. Ben J. Gu, Principal Science and Head of the Innate Phagocytosis Lab at the Florey Institute, University of Melbourne. Established in 2012, his lab focuses on pioneering novel diagnostic tools and therapeutic drugs for Alzheimer’s disease. We're honored to support their groundbreaking research with our INFORS HT bioreactors. "Our lab has been using INFORS HT bioreactors for nearly 10 years, from Minifors to Labfors. With their state-of-the-art design, we can easily optimize culture conditions for various applications. The stability and reliability of each batch are unmatched, allowing us to prepare our work as scheduled." - Dr. Ben Gu, Innate Phagocytosis Lab. 🔗Want to learn more about our bench-top bioreactors? https://ow.ly/F4RK50SnbTu #InforsHT #Bioreactors #ScientificInnovation #LabEfficiency #ResearchSupport #AlzheimersResearch #CustomerSatisfaction #ScientificBreakthroughs
To view or add a comment, sign in
-
-
We recently co-hosted an enlightening panel discussion with GenomeWeb, titled "PGx Testing Developments and Future Directions," featuring industry luminaries Dr. Vicky Pratt, past president of AMP; Dr. Bronwyn Ramey, Director of Precision Medicine at LetsGetChecked; and Glenn Sawyer, Associate Director for Clinical Genetics at Agena Bioscience. This panel delved deep into the evolving landscape of Pharmacogenomics (PGx) testing and its pivotal role in shaping the future of precision medicine. Here are three key takeaways: 1. PGx has made great advancements benefiting healthcare, particularly in the areas of chemotherapy drug toxicity profiling (DPYD) and psychotropics (anxiety and depression). 2. Significant challenges remain that slow the widespread adoption of PGx, including reimbursement and clinician/physician awareness and education as to the benefits of PGx testing. 3. The field of PGx is rapidly advancing and shows great promise for reducing adverse drug events and improving patient safety, particularly in the areas of cardiac, oncology and pain management drug selection, dosing, and treatments. If you missed the live session, don't worry! Watch the replay here: https://lnkd.in/gsjHYBWH #PrecisionMedicine #PGxTesting #Webinar #HealthcareInnovation #Pharmacogenomics #PGx
To view or add a comment, sign in
-
Corporate Development Executive | Innovative Business Growth Via M&A, Partnerships and Investments | Focus on Tech-Driven Advancements in Healthcare, Life Sciences, and Digital Health | Thought Leader and Change Agent
Stephanie Fraley and her team at the University of California San Diego present Digital DNA Melting Analysis, an innovative method for faster and more accurate pathogen detection than traditional blood cultures. Published in The Journal of Molecular Diagnostics, this technique provides results in under six hours, a significant improvement over the prolonged 15 hours to several days required by conventional methods. Crucial in scenarios like pediatric sepsis, this advancement emphasizes the importance of timely and precise diagnosis, potentially reducing unnecessary antibiotic exposure and improving patient outcomes. #DigitalDNAMelting #DNAAnalysis #PathogenDetection #FutureOfHealthcare #Healthcare Explore the detailed insights at https://lnkd.in/gFnU5-3M
To view or add a comment, sign in
-
-
Thank you to The Kennedy Trust for Rheumatology Research for inviting me to provide a testimony for their latest booklet, titled "Building on a breakthrough: the lasting impact of biologic therapy." Seeing this booklet published in 2024 and on #NationalPatientAdvocacyDay feels quite fitting, as I 'celebrate' my 20th anniversary with anti-TNF therapy! Here is what I had to say (check out pages 10 and 11 for other testimonies from the rheumatology community): "Access to biological anti-TNF therapy in 2004 at the age of 10 transformed my life from one controlled by a disease to one where I was in control. Having lived with juvenile idiopathic arthritis from a very young age, I struggled with active disease for several years, and was intolerant to the standard of care therapy. As a consequence, I did not adhere to treatment, and had crippling anxiety at the thought of treatment. I was struggling to mobilise, and had little to look forward to in life. Within a matters of weeks of treatment with anti-TNF therapy, life began to change. I could walk. I didn’t feel sick every weekend. I began to see what life could be like." Looking back, it's no wonder that I was destined for a career in #PatientAdvocacy and #MedicalAffairs within the pharmaceutical industry... when your very existence depends on access to treatment, your outlook irreversibly changes. It's an understanding that people who don't have chronic health conditions will never truly appreciate, and is why integrated #PatientEngagement in all aspects and phases of clinical research is critical. I will forever be indebted to the patients, researchers, and healthcare professionals whose contributions helped to transform my life... and it's the reason why I continue to do what I do... so we can improve lives for the better, collectively. #MedicalCommunications #MedComms #MedAffairs #PatientAdvocate #Advocacy #PatientAdvocacy #PatientsInvolved #PatientsIncluded #NothingAboutUsWithoutUs #IntegratedPatientEngagement
Over 30 years ago, the Kennedy Trust supported the early research and clinical trials that led to the discovery of anti-TNF therapy, a groundbreaking treatment that has improved the lives of millions of patients with musculoskeletal and inflammatory diseases across the globe. Recognising the importance of conserving this historic impact journey for prosperity, we recently undertook a 2-year project to catalogue the original research papers relating to the discovery. The Kennedy Trust Archive is now publicly available at the Wellcome Collection thanks to the work of our dedicated archivist Annie Lord. To mark the completion of this archiving project, and to celebrate the 25th anniversary of the first licencing of infliximab in the US and EU, we are thrilled to announce the launch of our new booklet “Building on a breakthrough: the lasting impact of biologic therapy.” The booklet chronicles the revolutionary anti-TNF discovery story and highlights the rich history of the Kennedy Trust and our ongoing efforts to further the field of musculoskeletal and inflammatory disease research. Read the booklet online here: https://lnkd.in/eFmTX6Je
Building on a breakthrough: the lasting impact of biologic therapy
https://www.kennedytrust.org
To view or add a comment, sign in
-
Sales Executive I Management Consultant | Healthcare Biotech | Diagnostics | Genomics / Digital Health | Passionate about bringing genomic medicine into routine clinical care and improving patient outcomes
Find ClearNote Health at the World CB & CDx Summit in Boston - and learn more about the advantages of our Virtuoso Epigenomics Platform. #CDx #drugdevelopment #therapyresponse
📢 ClearNote Health will be at the 14th World CB & CDx Boston Summit from September 3rd to 6th. 📍 Find us at #Booth27 and learn more about the advantages of the Virtuoso Epigenomics Platform, our liquid based monitoring tools and the power of longitudinal analysis in your translational research program. Virtuoso empowers more efficient and effective drug development by providing insights into disease biology, therapy response, and resistance - all from a simple blood draw. Reach out to schedule a meeting in advance! #CDx #drugdevelopment #therapyresponse
To view or add a comment, sign in
-
-
Today, we celebrate #WorldHealthDay, and the efforts of the CLINSPECT-M consortium to integrate mass spectrometry-based #proteomics into systems medicine by developing of standardized start-to-finish, fit-for-purpose workflows for clinical specimens. Testing different #samplepreparation and MS protocols on two clinically relevant sample matrices (plasma and cerebrospinal fluid), the six study partners conducted two studies, implementing the most promising protocols from the first round into the second. It was a great example of how the expert-driven exchange of knowledge and best practices can result in direct practical improvements that benefit the scientific community and, ultimately, patients. And it was especially gratifying to see our iST-BCT and SP3-iST kits do so well! Read more about the study and its results: https://ow.ly/wfVw50R3o5k
To view or add a comment, sign in
-
-
Learn about DecisionDx-Melanoma as part of the #PersonalizedMedicine campaign: How a Genomic Test is Empowering Better, More Personalized Melanoma Care by Aaron S. Farberg, MD.
Mediaplanet NY is proud to announce the launch of our #PersonalizedMedicine campaign! Personalized Medicine has the potential to revolutionize healthcare by tailoring treatment plans to individual patients & harnessing the power of genomic information and advanced diagnostics. Pick up a copy in USA Today or click the link below to learn more. 🧬👩🔬 https://lnkd.in/dz--x8Tp Featuring content from the Personalized Medicine Coalition, OncoHost, Castle Biosciences, Inc., Audubon Bioscience #PrecisionCare #HealthcareInnovation
To view or add a comment, sign in